Background: The Multiple Sclerosis Functional Composite (MSFC) provides a focused and
sensitive evaluation of disability in patients with multiple sclerosis (MS) that may be more …

Background Scores on an outcome measurement instrument depend on the type and
settings of the instrument used, how instructions are given to patients, how professionals …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Background Laboratory evidence has shown that cannabinoids might have a
neuroprotective action. We investigated whether oral dronabinol (Δ 9-tetrahydrocannabinol) …

Background Fingolimod (FTY720), a sphingosine-1-phosphate–receptor modulator that
prevents lymphocyte egress from lymph nodes, showed clinical efficacy and improvement …

Purpose To examine the impact of age and cognitive reserve on cognitive functioning in
patients with breast cancer who are receiving adjuvant treatments. Patients and Methods …

Background Clinical studies suggested that fampridine (4-aminopyridine) improves motor
function in people with multiple sclerosis. This phase III study assessed efficacy and safety of …

Objective A previous phase 3 study showed significant improvement in walking ability in
multiple sclerosis (MS) patients treated with oral, extended‐release dalfampridine (4 …

Purpose To compare the neuropsychological functioning of breast cancer patients with
invasive cancer and noninvasive cancer prior to adjuvant treatment. Patients and Methods …

Importance Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who receive
approved disease-modifying therapies experience breakthrough disease and accumulate …